Company / Operating Cash Flow
Inhibikase Therapeutics, Inc. Operating Cash Flow History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$18.1M
FY2024
5-year range
-$18.1M / -$1.1M
FY2021-FY2024
Trend
-4.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 3 consecutive years, from -$1M in FY2021 to -$18M in FY2024.
Based on SEC 10-K filings.
-$18M in FY2024.
Declined from -$14M to -$18M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Inhibikase Therapeutics, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2024, operating cash flow decreased 4.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$18.1M | -4.2% |
| FY2023 | -$17.4M | -21.4% |
| FY2022 | -$14.3M | -1165.9% |
| FY2021 | -$1.1M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026